Genomic Valley Biotech Limited
BSE: GVBL · Biotechnology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Genomic Valley Biotech Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Genomic Valley Biotech Limited is an Indian company specialising in the cultivation, processing, and distribution of high-quality flowers and ornamental plants. It utilises greenhouse technologies to serve both commercial and retail segments within the domestic market.
Business Model
The company generates revenue through the sale of floral products and ornamental plants, leveraging its cultivation facilities in Haryana. It also explores biotechnology and tissue culture applications to improve crop yields and plant quality.
Management Commentary
Management focuses on maintaining a niche position within the organised floriculture industry while managing operational overheads from its New Delhi corporate office.
Growth Outlook
Growth is primarily driven by seasonal demand cycles and the company's ability to maintain its niche position in the Indian floriculture market. Future prospects remain tied to the successful application of biotechnology to enhance agricultural output.
Key Risks
- Seasonal Demand Volatility. The company's financial performance is highly sensitive to seasonal fluctuations and agricultural commodity cycles.
- Operational Scale Constraints. As a micro-cap entity, the company faces challenges in competing with larger agricultural conglomerates due to limited economies of scale.
- Agricultural and Climatic Risks. Reliance on greenhouse cultivation exposes the business to risks associated with crop health, pest management, and climate-related disruptions.
- Market Concentration. The company's focus on the domestic Indian market limits its ability to diversify revenue streams across different geographical regions.
Start your research today
Unlock AI insights, financials, peers and live data on Genomic Valley Biotech Limited and 5,000+ companies — free.
Peers · Biotechnology
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Genomic Valley Biotech LimitedGVBL | ₹9 Cr | — | — | — | 14.8% | — | — | -30.8% |
Anthem Biosciences Ltd.ANTHEM | ₹50,693 Cr | 131.02 | 53.09 | — | 47.5% | 18.9% | 25.4% | +10.0% |
Advanced Enzyme Technologies LimitedADVENZYMES | ₹3,357 Cr | 20.23 | 12.45 | 12.2% | 35.0% | 11.3% | 14.3% | -13.3% |
As of Mar 2026
Financials
Genomic Valley Biotech Limited
BSE: GVBL · Biotechnology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Genomic Valley Biotech Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Genomic Valley Biotech Limited is an Indian company specialising in the cultivation, processing, and distribution of high-quality flowers and ornamental plants. It utilises greenhouse technologies to serve both commercial and retail segments within the domestic market.
Business Model
The company generates revenue through the sale of floral products and ornamental plants, leveraging its cultivation facilities in Haryana. It also explores biotechnology and tissue culture applications to improve crop yields and plant quality.
Management Commentary
Management focuses on maintaining a niche position within the organised floriculture industry while managing operational overheads from its New Delhi corporate office.
Growth Outlook
Growth is primarily driven by seasonal demand cycles and the company's ability to maintain its niche position in the Indian floriculture market. Future prospects remain tied to the successful application of biotechnology to enhance agricultural output.
Key Risks
- Seasonal Demand Volatility. The company's financial performance is highly sensitive to seasonal fluctuations and agricultural commodity cycles.
- Operational Scale Constraints. As a micro-cap entity, the company faces challenges in competing with larger agricultural conglomerates due to limited economies of scale.
- Agricultural and Climatic Risks. Reliance on greenhouse cultivation exposes the business to risks associated with crop health, pest management, and climate-related disruptions.
- Market Concentration. The company's focus on the domestic Indian market limits its ability to diversify revenue streams across different geographical regions.
Start your research today
Unlock AI insights, financials, peers and live data on Genomic Valley Biotech Limited and 5,000+ companies — free.
Peers · Biotechnology
As of Mar 2026